ClinicalTrials.Veeva

Menu

Glutamatergic Amino Acids and Oxytocin Levels in the Plasma of Patients in First Psychotic Episode (FPE)- Before and After Neuroleptic Treatment

S

Shalvata Mental Health Center

Status

Unknown

Conditions

Schizophreniform
Schizophrenia
Schizoaffective Disorder
Brief Psychotic Episode

Study type

Observational

Funder types

Other

Identifiers

NCT00789022
uriel111

Details and patient eligibility

About

The goal of our research is to check the levels of D-Serine, Glycine, and other Glutamatergic amino acids, in patients with First Psychotic Episode (FPE). These patients are in the early stage of the disease, treated with neuroleptics for short periods of time, and are usually hospitalized for the first time. The hypothesis of the research is that we will find low levels of Glycine and D-Serine in these patients. Following an Anti-psychotic treatment we will expect these levels to return to the norm, and that this correction will be accompanied by a reduction of positive and negative symptoms.

In addition, we will check the D-Serine and Glycine levels in the plasma of first degree relatives of the patients and a group of healthy subjects. The results of this study might support the hypothesis that the Glutamatergic system in involved in the pathology of Schizophrenia from it's early stages.

In addition, we will check the levels of Oxytocin and Estrogen in the plasma of patients in FPE. Our hypothesis is that we will find low levels of Estrogen and High levels of Oxytocin in this group of patients. The results of the study might support the hypothesis that Estrogen and Oxytocin are involved in the pathology of Schizophrenia from it's early stages.

Enrollment

80 estimated patients

Sex

All

Ages

18 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Subjects between 18-60 years
  • Clinical Diagnosis of Schizophrenia, Schizophreniphorm disorder, Schizoaffective Disorder, Brief esychotic episode

Exclusion criteria

  • two years or more of positive symptoms
  • Neuroleptic treatment for more then twe weeks in the prior month, or for more then six weeks at any time.
  • Drug induced psychotic episode

Trial design

80 participants in 3 patient groups

1
Description:
40 subjects in a First Psychotic Episode
2
Description:
20 First Degree relatives
3
Description:
20 Healthy subjects

Trial contacts and locations

1

Loading...

Central trial contact

Uriel Levi-Herscho, MD; Uri Nitzan, Md

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems